Information about pipeline products


A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
Lee JH, Chen TWW, Hsu CH, et al.
Invest New Drugs. 2020;38(1):99-110.
An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma
Izutsu K, Makita S, Nosaka K, et al.
Blood. 2023;141(10):1159-1168.
Breast Cancer
Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer
Garrido C, Manoogian M, Ghambire D, et al.
Virchows Arch. 2023. doi: 10.1007/s00428-023-03671-x. Online ahead of print.
Breast Cancer
Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: Results from a phase Ib study
Modi S, Park H, Murthy RK, et al.
J Clin Oncol. 2020;38(17):1887-1896.
Lung Cancer Other/Multi-Tumor
Application of the model-informed drug development paradigm to datopotamab deruxtecan dose selection for late-stage development
Lu Y, Liang S, Hong Y, et al.
CPT Pharmacometrics Syst Pharmacol. 2023. doi: 10.1002/psp4.13058. Online ahead of print.
Changes in HER3 expression profiles between primary and recurrent gynecological cancers
Kojima Y, Sudo K, Yoshida H, et al.
Kojima et al. Cancer Cell International (2023) 23:18
Lung Cancer
Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan
Baba T, Kusumoto M, Kato T, et al.
Baba et al. Int J Clin Oncol. 2023 Dec;28(12):1585-1596. doi: 10.1007/s10147-023-02414-x. Epub 2023 Oct 3.
Clinical outcomes in patients with FLT3-ITD-mutated relapsed/refractory acute myelogenous leukemia undergoing hematopoietic stem cell transplantation after quizartinib or salvage chemotherapy in the QUANTUM-R trial
Ganguly S, Cortes JE, Kramer A, et al.
Transplant Cell Ther. 2021;27(2):153-162.
Breast Cancer
Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland
Paulissen JHJ, Seddik AH, Dunton KJ, et al.
Eur J Health Econ. 2023. doi: 10.1007/s10198-023-01617-3. Online ahead of print.
Lung Cancer
Current and emerging treatment options for patients with metastatic EGFR-mutated non-small cell lung cancer after progression on osimertinib and platinum-based chemotherapy: A podcast discussion
Patel S, Patel JD.
Adv Ther. 2023;40(12):5579-5590.
Pages: 1  2  3  4  5  6  7